Inhibitor Therapeutics's total assets is $250K.
Get informed when a big investor buys or sells
+ FollowLatest change versus the prior comparable period (same company).
Inhibitor Therapeutics's total assets stands at $250K as of September 2026. That compares with $3.1M in the prior-year period — down 92.1% year over year. Stockcircle updates this page with the newest filings so you can track how the metric evolves quarter by quarter.
Inhibitor Therapeutics reported $250K in total assets versus $3.1M a year earlier — a 92.1% year-over-year decrease. The historical chart on this page makes it easier to see whether that move is part of a longer pattern.
That compares with $3.1M in the prior-year period — down 92.1% year over year. Sustained growth in total assets can support a stronger franchise, while sharp declines may reflect divestitures, weaker demand, or accounting changes. Always read YoY moves with the footnotes of recent filings in mind.
The history chart shows how Inhibitor Therapeutics's total assets evolved across reporting periods, while the comparison chart places INTI next to similar companies. Use both: a rising metric that still lags peers tells a different story than a rising metric that already leads the group. Growth charts, when available, highlight acceleration or slowdown.
Yes — within Healthcare, total assets is commonly used to spot outliers. Inhibitor Therapeutics's reading of $250K is a starting point; confirm whether differences come from growth, margins, accounting choices, or one-time items before treating an outlier as a buy or sell signal.